Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

IQV US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

IQV US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Iqvia Holdings Inc.(IQV US)

$265.12-5.992.21%Ext:$270.83+5.712.15%(Market Closed · 00:56:08 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Iqvia Holdings Inc.(IQV US)

$265.12-5.992.21%Ext:$270.83+5.712.15%(Market Closed · 00:56:08 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Iqvia Holdings Inc. — Company Profile

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Sector
Industrials
Industry
Professional Services
Exchange
UN
CEO
Ari Bousbib
Headquarters
Durham, NC, US
IPO Date
May 9, 2013
Employees
94,000
Website
www.iqvia.com

Key Metrics

Price
$258.21
Market Cap
$42.50B
Revenue (TTM)
$4.15B
Net Income (TTM)

Iqvia Holdings Inc. — Company Profile

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Sector
Industrials
Industry
Professional Services
Exchange
UN
CEO
Ari Bousbib
Headquarters
Durham, NC, US
IPO Date
May 9, 2013
Employees
94,000
Website
www.iqvia.com

Key Metrics

Price
$258.21
Market Cap
$42.50B
Revenue (TTM)
$4.15B
Net Income (TTM)
$274.00M
EPS (TTM)
1.63
P/E (TTM)
30.69
P/B (TTM)
6.83
Dividend Yield
0.00%
ROE (TTM)
4.40%
ROA (TTM)
0.92%
Operating Margin
12.38%
Beta
0.76

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Website
www.iqvia.com
Location
Durham, NC, US
Phone919 998 2000
Employees94,000
CEOAri Bousbib
Sector
Industrials
Industry
Professional Services
IPO DateMay 9, 2013

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.1K)

Expand
  • Form 4Sherbet Eric12 Nov
  • Form 4Wims Morris Leslie9 Nov
  • Form 4GOGGINS COLLEEN A9 Nov
  • Form 4Fasano Jim9 Nov
  • Form 4DANHAKL JOHN G9 Nov
  • Form 144Sherbet Eric9 Nov
  • 10-QQ3ended 30 Sept 202627 Oct
  • 8-KResults of Operations and Financial Condition27 Oct
  • 8-KEntry into a Material Definitive Agreement23 Sep
  • 8-KIQVIA Announces Offering of Senior Notes9 Sep
  • Form 4Berkshire James G.4 Sep
  • Form 144Berkshire James G.2 Sep
  • Form 4STAUB W RICHARD4 Aug
  • Form 4Patel Bhavik4 Aug
  • Form 144STAUB W RICHARD3 Aug
  • Form 4Sherbet Eric31 Jul
  • Form 4Cherofsky Keriann31 Jul
  • Form 4BOUSBIB ARI31 Jul
  • Form 144Patel Bhavik31 Jul
  • Form 144Cherofsky Keriann29 Jul

News

  • IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know11:16AM
  • IQVIA Holdings Inc. $IQV Stock Holdings Decreased by CenterBook Partners LP03:57AM
  • Artisan Select Equity Fund Q3 2026 Portfolio Review12 Nov
  • IQVIA: 3 Key Takeaways for Long-Term Investors9 Nov
  • Artisan Global Value Fund Q3 2026 Portfolio Discussion29 Oct
  • Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock29 Oct
  • IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI28 Oct
  • What IQVIA (IQV) Said on Its Q3 Earnings Call27 Oct
  • IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y27 Oct
  • IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates27 Oct
  • IQVIA Reports Third-Quarter 2026 Results27 Oct
  • IQVIA Reports Third-Quarter 2026 Results27 Oct
  • IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know22 Oct
  • IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution20 Oct
  • IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?20 Oct
  • IQVIA Holdings Inc. $IQV Stock: Maia Wealth LLC Reduces Stake20 Oct
  • First Citizens Bank & Trust Co. Makes New $1.39 Million Investment in IQVIA Holdings Inc. $IQV16 Oct
  • IQVIA Selects Veeva Clinical Operations Applications13 Oct
  • IQVIA Selects Veeva Clinical Operations Applications13 Oct
  • Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock8 Oct

Mentions in Filings

  • … ge solutions provider, from 2021 to September 2023, and as Chief Accounting Officer of Syneos Health, Inc., a clinical research and commercialization services company, from 2018 to 2021. Mr. Parks also was employed by <strong>IQVIA Holdings</strong>, Inc. (formerly Quintiles), a biopharmaceutical services company, from 2011 to 2018, holding positions of increasing --- responsibility, including Senior Vice President, Corporate Controller and Principal Accounting …
    Guardant Health, Inc.Iqvia Holdings Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·3 Nov
  • … ivate companies in short and long term cash, capital planning and strategies. From May 2013 until February 2016, Ms. Peck served as the Vice President Finance, Global Services for IMS Health Inc. (“IMS Health,” now <strong>IQVIA Holdings Inc.</strong>), a technology and analytics company serving life sciences companies near Danbury, Connecticut. From November 2009 until May 2013, Ms. Peck was Vice President Financial Planning and Analysis for IMS Health. From May …
    LIGHTPATH TECHNOLOGIES INCIqvia Holdings Inc.·DEF 14A - Definitive proxy statement·Q2 27·26 Oct
  • … are trademarks registered in the name of Dr. Reddy’s Laboratories Limited or are pending before the respective trademark registries, unless otherwise specified. Market share data is based on information provided by <strong>IQVIA Holdings Inc.</strong> (formerly Quintiles IMS Holdings Inc.) (“IQVIA”), a provider of market research to the pharmaceutical industry, unless otherwise stated. References to “HUF” are to a Hindu Undivided Family, a form of entity found in …
    DR REDDYS LABORATORIES LTDIqvia Holdings Inc.·6-K - Current report (foreign private issuer)·Q3 27·23 Oct
  • … ions from providers that make applications geared toward the life sciences industry. Our CRM solutions primarily compete with Salesforce, Inc., which has developed a life sciences industry-specific CRM application. <strong>IQVIA Holdings Inc.</strong>, which historically offered a competitive CRM solution, has licensed its CRM software to Salesforce. Our Veeva Data Cloud products as well as Veeva Crossix, compete with IQVIA, Ipsos Group S.A., Definitive Health Co …
    VEEVA SYSTEMS INCIqvia Holdings Inc.·10-Q - Quarterly report Q2·Q2 27·27 Aug
  • #\*Iovance Biotherapeutics, Inc. 49,131 125,284 \*IQVIA Holdings, Inc. 48,721 11,213,138 iRadimed Corp. 1,493 146,135 \*Ironwood Pharmaceuticals, Inc., Class A 626 3,061 \*Jazz Pharmaceuticals PLC 15,743 2,589,566 Johnson & Johnson 690,976 157,024,296 \* Keros Therapeutics, Inc. 1,693 30,322 \*Kewaunee Scientific Corp. 684 27,045 \* Kiniksa Pharmaceuticals International PLC, Class A 10,659 468,143 …
    Dimensional ETF TrustIqvia Holdings Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … oduced differently” than display ads. Id. at 126-32. 106.Social media ads and display ads likewise serve different purposes and are therefore not substitutes, as a Court in this District recently found. See FTC v. <strong>IQVIA Holdings Inc.</strong>, 710 F. Supp. 3d 329, 367-68 (S.D.N.Y. 2024). Social media ads appear in a user’s social media feed and are targeted to users based on the social media content they read or watch. Display ads, by contrast, are often …
    Teads Holding Co.Iqvia Holdings Inc.·EX-99.2 - 8-K - Regulation FD Disclosure·Q3 26·3 Aug

Key Stats

Trading

Px/Chg 1D$258.21 / -0.96%
Avg Volume1.80M
Beta0.76
Mkt Cap42.50B
FD Mkt Cap42.42B

Float

Shrs Out/Float164.60M / 156.25M
Short Float0.03%
Days to Cover2.74
Stock Repurchased$552.00M

Current Valuation

EV56.75B
EV/EBITDA16.13
EV/Sales3.41
P/B6.83
P/S2.56
FCF Yield1.16%
ROE4.40%
ROA0.92%
Current Ratio0.75

Estimates

P/E30.69
Est P/E0.00
Est EPS2.82
Est PEG0.00

Valuation

Metric5Yr AvgApr '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings58.3131.5831.5320.1153.23155.11
Price / Sales4.712.392.861.796.2710.24
Price / Book Value5.715.987.004.554.216.83
Price / Free Cash Flow39.7321.7228.5413.0648.7786.56
ENTERPRISE VALUE METRICS
Enterprise Value48,015.646,249.655,334.440,066.041,680.856,747.4
Enterprise Value / Sales6.553.213.692.609.5513.67
Enterprise Value / EBITDA30.9115.9016.9911.6039.8170.23
Enterprise Value / EBIT47.0626.0025.9717.1357.10109.13

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%13,874.014,410.014,984.015,405.016,310.0
Gross Income-2%4,641.05,028.05,239.05,375.04,286.0
EBITDA5.8%2,767.02,909.03,256.03,453.03,464.0
EBIT11.5%1,503.01,779.02,131.02,339.02,320.0
Net Income8.9%966.01,091.01,358.01,373.01,360.0
EPS (Diluted)12.2%4.955.727.297.497.84
BALANCE SHEET
Cash & ST Inv9.7%1,477.01,309.01,496.01,843.02,141.0
Total Assets4.9%24,689.025,337.026,681.026,899.029,944.0
Total Liabilities5.7%18,647.019,572.020,569.020,832.023,314.0
Total Shareholder Equity1.9%6,042.05,765.06,112.06,067.06,503.0
CASH FLOW
Net Operating Cash Flow-2.5%2,942.02,260.02,149.02,716.02,654.0
Cap Ex-1.5%-640.0-674.0-649.0-602.0-603.0
Free Cash Flow-2.8%2,302.01,586.01,500.02,114.02,051.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)266.48
Basic Shares164.60
Market Cap43,862.6
Diluted Shares167.00
Fully Diluted Shares Outstanding167.00
Fully Diluted Market Cap44,502.2
+Consolidated Debt16,314.0
−In-the-Money Convertible Debt—
+Capital Leases247.0
+Operating Leases—
−Cash & Equivalents-2,249.0
−Short-term Investments-173.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest131.0
+Pension Liabilities—
Enterprise Value58,058.6

Segment data

Revenue

by Products and services

  • Research And Development Solutions55%
  • Technology And Analytics Solutions41%
  • Contract Sales And Medical Solutions5%

Revenue

by Geography

  • Americas47%
  • Emea32%
  • Asia Pacific21%

Related companies

Wanhua Chemical Group Co., Ltd.

600309 CG

Novozymes As/fi

NVZMY US

DSM-Firmenich AG/ADR

DSFIR NA

L Air Liquide Sa /FI

AIQUY US

EMS-Chemie Holding AG/ADR

EMSHF US

Incyte Corp

INCY US

Grace Fabric Technology Co.,Ltd.

603256 CG

Medpace Holdings, Inc.

MEDP US

Nippon Paint Holdings Co., Ltd.

NPCPF US

Covestro AG/ADR

COVTY US

Symrise AG

SYIEY US

Charles River Laboratories International, Inc.

CRL US

$274.00M
EPS (TTM)
1.63
P/E (TTM)
30.69
P/B (TTM)
6.83
Dividend Yield
0.00%
ROE (TTM)
4.40%
ROA (TTM)
0.92%
Operating Margin
12.38%
Beta
0.76

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Website
www.iqvia.com
Location
Durham, NC, US
Phone919 998 2000
Employees94,000
CEOAri Bousbib
Sector
Industrials
Industry
Professional Services
IPO DateMay 9, 2013

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.1K)

Expand
  • Form 4Sherbet Eric12 Nov
  • Form 4Wims Morris Leslie9 Nov
  • Form 4GOGGINS COLLEEN A9 Nov
  • Form 4Fasano Jim9 Nov
  • Form 4DANHAKL JOHN G9 Nov
  • Form 144Sherbet Eric9 Nov
  • 10-QQ3ended 30 Sept 202627 Oct
  • 8-KResults of Operations and Financial Condition27 Oct
  • 8-KEntry into a Material Definitive Agreement23 Sep
  • 8-KIQVIA Announces Offering of Senior Notes9 Sep
  • Form 4Berkshire James G.4 Sep
  • Form 144Berkshire James G.2 Sep
  • Form 4STAUB W RICHARD4 Aug
  • Form 4Patel Bhavik4 Aug
  • Form 144STAUB W RICHARD3 Aug
  • Form 4Sherbet Eric31 Jul
  • Form 4Cherofsky Keriann31 Jul
  • Form 4BOUSBIB ARI31 Jul
  • Form 144Patel Bhavik31 Jul
  • Form 144Cherofsky Keriann29 Jul

News

  • IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know11:16AM
  • IQVIA Holdings Inc. $IQV Stock Holdings Decreased by CenterBook Partners LP03:57AM
  • Artisan Select Equity Fund Q3 2026 Portfolio Review12 Nov
  • IQVIA: 3 Key Takeaways for Long-Term Investors9 Nov
  • Artisan Global Value Fund Q3 2026 Portfolio Discussion29 Oct
  • Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock29 Oct
  • IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI28 Oct
  • What IQVIA (IQV) Said on Its Q3 Earnings Call27 Oct
  • IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y27 Oct
  • IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates27 Oct
  • IQVIA Reports Third-Quarter 2026 Results27 Oct
  • IQVIA Reports Third-Quarter 2026 Results27 Oct
  • IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know22 Oct
  • IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution20 Oct
  • IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?20 Oct
  • IQVIA Holdings Inc. $IQV Stock: Maia Wealth LLC Reduces Stake20 Oct
  • First Citizens Bank & Trust Co. Makes New $1.39 Million Investment in IQVIA Holdings Inc. $IQV16 Oct
  • IQVIA Selects Veeva Clinical Operations Applications13 Oct
  • IQVIA Selects Veeva Clinical Operations Applications13 Oct
  • Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock8 Oct

Mentions in Filings

  • … ge solutions provider, from 2021 to September 2023, and as Chief Accounting Officer of Syneos Health, Inc., a clinical research and commercialization services company, from 2018 to 2021. Mr. Parks also was employed by <strong>IQVIA Holdings</strong>, Inc. (formerly Quintiles), a biopharmaceutical services company, from 2011 to 2018, holding positions of increasing --- responsibility, including Senior Vice President, Corporate Controller and Principal Accounting …
    Guardant Health, Inc.Iqvia Holdings Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·3 Nov
  • … ivate companies in short and long term cash, capital planning and strategies. From May 2013 until February 2016, Ms. Peck served as the Vice President Finance, Global Services for IMS Health Inc. (“IMS Health,” now <strong>IQVIA Holdings Inc.</strong>), a technology and analytics company serving life sciences companies near Danbury, Connecticut. From November 2009 until May 2013, Ms. Peck was Vice President Financial Planning and Analysis for IMS Health. From May …
    LIGHTPATH TECHNOLOGIES INCIqvia Holdings Inc.·DEF 14A - Definitive proxy statement·Q2 27·26 Oct
  • … are trademarks registered in the name of Dr. Reddy’s Laboratories Limited or are pending before the respective trademark registries, unless otherwise specified. Market share data is based on information provided by <strong>IQVIA Holdings Inc.</strong> (formerly Quintiles IMS Holdings Inc.) (“IQVIA”), a provider of market research to the pharmaceutical industry, unless otherwise stated. References to “HUF” are to a Hindu Undivided Family, a form of entity found in …
    DR REDDYS LABORATORIES LTDIqvia Holdings Inc.·6-K - Current report (foreign private issuer)·Q3 27·23 Oct
  • … ions from providers that make applications geared toward the life sciences industry. Our CRM solutions primarily compete with Salesforce, Inc., which has developed a life sciences industry-specific CRM application. <strong>IQVIA Holdings Inc.</strong>, which historically offered a competitive CRM solution, has licensed its CRM software to Salesforce. Our Veeva Data Cloud products as well as Veeva Crossix, compete with IQVIA, Ipsos Group S.A., Definitive Health Co …
    VEEVA SYSTEMS INCIqvia Holdings Inc.·10-Q - Quarterly report Q2·Q2 27·27 Aug
  • #\*Iovance Biotherapeutics, Inc. 49,131 125,284 \*IQVIA Holdings, Inc. 48,721 11,213,138 iRadimed Corp. 1,493 146,135 \*Ironwood Pharmaceuticals, Inc., Class A 626 3,061 \*Jazz Pharmaceuticals PLC 15,743 2,589,566 Johnson & Johnson 690,976 157,024,296 \* Keros Therapeutics, Inc. 1,693 30,322 \*Kewaunee Scientific Corp. 684 27,045 \* Kiniksa Pharmaceuticals International PLC, Class A 10,659 468,143 …
    Dimensional ETF TrustIqvia Holdings Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … oduced differently” than display ads. Id. at 126-32. 106.Social media ads and display ads likewise serve different purposes and are therefore not substitutes, as a Court in this District recently found. See FTC v. <strong>IQVIA Holdings Inc.</strong>, 710 F. Supp. 3d 329, 367-68 (S.D.N.Y. 2024). Social media ads appear in a user’s social media feed and are targeted to users based on the social media content they read or watch. Display ads, by contrast, are often …
    Teads Holding Co.Iqvia Holdings Inc.·EX-99.2 - 8-K - Regulation FD Disclosure·Q3 26·3 Aug

Key Stats

Trading

Px/Chg 1D$258.21 / -0.96%
Avg Volume1.80M
Beta0.76
Mkt Cap42.50B
FD Mkt Cap42.42B

Float

Shrs Out/Float164.60M / 156.25M
Short Float0.03%
Days to Cover2.74
Stock Repurchased$552.00M

Current Valuation

EV56.75B
EV/EBITDA16.13
EV/Sales3.41
P/B6.83
P/S2.56
FCF Yield1.16%
ROE4.40%
ROA0.92%
Current Ratio0.75

Estimates

P/E30.69
Est P/E0.00
Est EPS2.82
Est PEG0.00

Valuation

Metric5Yr AvgApr '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings58.3131.5831.5320.1153.23155.11
Price / Sales4.712.392.861.796.2710.24
Price / Book Value5.715.987.004.554.216.83
Price / Free Cash Flow39.7321.7228.5413.0648.7786.56
ENTERPRISE VALUE METRICS
Enterprise Value48,015.646,249.655,334.440,066.041,680.856,747.4
Enterprise Value / Sales6.553.213.692.609.5513.67
Enterprise Value / EBITDA30.9115.9016.9911.6039.8170.23
Enterprise Value / EBIT47.0626.0025.9717.1357.10109.13

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%13,874.014,410.014,984.015,405.016,310.0
Gross Income-2%4,641.05,028.05,239.05,375.04,286.0
EBITDA5.8%2,767.02,909.03,256.03,453.03,464.0
EBIT11.5%1,503.01,779.02,131.02,339.02,320.0
Net Income8.9%966.01,091.01,358.01,373.01,360.0
EPS (Diluted)12.2%4.955.727.297.497.84
BALANCE SHEET
Cash & ST Inv9.7%1,477.01,309.01,496.01,843.02,141.0
Total Assets4.9%24,689.025,337.026,681.026,899.029,944.0
Total Liabilities5.7%18,647.019,572.020,569.020,832.023,314.0
Total Shareholder Equity1.9%6,042.05,765.06,112.06,067.06,503.0
CASH FLOW
Net Operating Cash Flow-2.5%2,942.02,260.02,149.02,716.02,654.0
Cap Ex-1.5%-640.0-674.0-649.0-602.0-603.0
Free Cash Flow-2.8%2,302.01,586.01,500.02,114.02,051.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)266.48
Basic Shares164.60
Market Cap43,862.6
Diluted Shares167.00
Fully Diluted Shares Outstanding167.00
Fully Diluted Market Cap44,502.2
+Consolidated Debt16,314.0
−In-the-Money Convertible Debt—
+Capital Leases247.0
+Operating Leases—
−Cash & Equivalents-2,249.0
−Short-term Investments-173.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest131.0
+Pension Liabilities—
Enterprise Value58,058.6

Segment data

Revenue

by Products and services

  • Research And Development Solutions55%
  • Technology And Analytics Solutions41%
  • Contract Sales And Medical Solutions5%

Revenue

by Geography

  • Americas47%
  • Emea32%
  • Asia Pacific21%

Related companies

Wanhua Chemical Group Co., Ltd.

600309 CG

Novozymes As/fi

NVZMY US

DSM-Firmenich AG/ADR

DSFIR NA

L Air Liquide Sa /FI

AIQUY US

EMS-Chemie Holding AG/ADR

EMSHF US

Incyte Corp

INCY US

Grace Fabric Technology Co.,Ltd.

603256 CG

Medpace Holdings, Inc.

MEDP US

Nippon Paint Holdings Co., Ltd.

NPCPF US

Covestro AG/ADR

COVTY US

Symrise AG

SYIEY US

Charles River Laboratories International, Inc.

CRL US